Five IPOs raised $1.4 billion this week, bringing the year's total up to 50 IPOs raising $15 billion. Set to be the week's largest offerings, two energy companies struggled: Antero Midstream GP broke issue while Liberty postponed. A mortgage REIT and three...read more
Ovid Therapeutics, an early stage biotech developing treatments for rare neurodevelopmental disorders, raised $75 million by offering 5 million shares at $15, the low end of the range of $15 to $17. Ovid Therapeutics plans to list on the Nasdaq under the...read more
The IPO market continues to heat up with six deals on the calendar aiming to raise $1.7 billion in the first week of May. They include three biotechs, two energy companies and...read more
Ovid Therapeutics, a clinical-stage biotech developing treatments for rare neurological disorders, announced terms for its IPO on Tuesday.
The New York, NY-based company plans to raise $80 million by offering 5 million shares at a price range of $15 to $17....read more
US IPO Weekly Recap: Biotechs and energy fail to excite in 5-IPO week
Five IPOs raised $1.4 billion this week, bringing the year's total up to 50 IPOs raising $15 billion. Set to be the week's largest offerings, two energy companies struggled: Antero Midstream GP broke issue while Liberty postponed. A mortgage REIT and three...read more
Ovid Therapeutics prices IPO at $15, the low end of the range
Ovid Therapeutics, an early stage biotech developing treatments for rare neurodevelopmental disorders, raised $75 million by offering 5 million shares at $15, the low end of the range of $15 to $17. Ovid Therapeutics plans to list on the Nasdaq under the...read more
US IPO Week Ahead: May starts strong with 6 IPOs featuring energy and biotech
The IPO market continues to heat up with six deals on the calendar aiming to raise $1.7 billion in the first week of May. They include three biotechs, two energy companies and...read more
Rare neurological disorder biotech Ovid Therapeutics sets terms for $80 million IPO
Ovid Therapeutics, a clinical-stage biotech developing treatments for rare neurological disorders, announced terms for its IPO on Tuesday. The New York, NY-based company plans to raise $80 million by offering 5 million shares at a price range of $15 to $17....read more